~~<i id='CE834BB022'><strike id='CE834BB022'><tt id='CE834BB022'><pre id='CE834BB022'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：knowledge 2025-09-05 07:02:18 - browse：511

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare drug price negotiation program allowed for now

Wikipedia

hotspot

leisure time

hotspot

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb

WSS

AI models in health care face new federal disclosure requirements

Listen: Who gets the credit for GLP

Chemotherapy shortages won’t get better under Biden’s latest plan

Why sickle cell disease is getting the first CRISPR treatment

CMS should re

After sickle

hotspot

hotspot

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Cigna to pay $172 million to settle Medicare Advantage fraud probe

State Dept. review finds Biden bears some blame for Afghanistan failures

Kaiser Permanente unions announce official strike date

Heart attack and stroke risk calculators need revising

Menendez indictment could see pharma lose a key ally

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Menendez indictment could see pharma lose a key ally

Supreme Court strikes down use of affirmative action

Intercept Pharmaceuticals sells itself for less than $1 billion

hotspot

Did you have Obamacare on your GOP debate bingo card?

Pfizer plans to depart BIO

The woman behind the Dana Farber

FDA seeks to regulate lab

Paxlovid should be available without a positive Covid test

Shingles, which affected Dianne Feinstein, is on the rise

hotspot

leisure time

hotspot

hotspot